 |
The Company
| Who: |
Immuno-Genic Corporation, IGC, was incorporated in Nevada in October
of 2001. IGC is a private company with 271 shareholders. |
| What: |
IGC is a Medical Device Research & Development Company Specializing
in Immune Modulation Therapy, IMT, to; Control Inflammation, Attenuate
Acute and Chronic Pain, Mediate the Disease Process and to Accelerate the
Healing Process through the control of the body's natural Nitric Oxide (NO) response. |
| Why: |
| Vision: |
IGC's vision is to provide improved "Quality of Life" through the
advancement of tomorrow's healthcare today, for all mammals, veterinary and
human. |
| Mission: |
The IGC mission is to advance to the top of the field of Bio-photonic medicine with its patented, breakthrough, Photoceutical™ technology. |
|
| Where: |
IGC's Home office is located at:
921 South Ridgewood Avenue
Daytona Beach, Florida 32114
The West Coast office is located at:
5380 Boyer Road
Mariposa, California 95338. |
| When: |
IGC is planning to launch its proprietary human and veterinary treatment
devices during 2012. The Company is anticipating the completion of
two clinical trials concerning the attenuation of ocular pain and musculoskeletal
pain in humans. The studies are proposed to be conducted at the Perelman
Center for Advanced Medicine in Pennsylvania, in association with the Scheie
Eye Institute. IGC has received a proposal that the Company is pursuing to open
medical clinics in several Caribbean countries. This opportunity and the
regulatory environment in the Caribbean would allow the Company to offer
treatment to humans and to begin generating revenue immediately upon the
significant savings to the Company. |
|
|
 |
